Abstract
OBJECTIVE: To determine whether changes in subcutaneous adipose tissue plasminogen activator inhibitor-1 (PAI-1) expression influence plasma PAI-1 level during weight loss in obese humans.
DESIGN: Study of the variations of PAI-1 levels both in plasma and in subcutaneous abdominal adipose tissue in 15 volunteer non-diabetic obese subjects, body mass index (BMI) 40.4.±1.9 kg/m2, aged 48±3 y, before and after a 3 week very low calorie diet (VLCD) programme (3.9±0.1 MJ/day).
MEASUREMENTS: Plasma and adipose tissue PAI-1 protein levels were measured by enzyme-linked immunosorbent assay and PAI-1 mRNA levels were quantified by quantitative RT-competitive PCR.
RESULTS: VLCD induced weight loss (5.8±0.8 kg) and decreased plasma PAI-1 concentration (−26% (P<0.01)). Surprisingly, PAI-1 mRNA and protein abundance in subcutaneous adipose tissue increased by 87% (P<0.05) and by 44% (P<0.01), respectively.
CONCLUSION: These data indicate thus that changes in subcutaneous adipose tissue PAI-1 expression are not involved in the decrease of plasma PAI-1 levels during VLCD in obese subjects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B . Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction Lancet 1987 2:: 3–9.
Juhan-Vague I, Alessi MC . PAI-1, obesity, insulin resistance and risk of cardiovascular events Thromb Haemost 1997 78:: 656–660.
Folsom AR, Qamhieh HK, Wing RR, Jeffrey RW, Stinson VL, Kuller LH, Wu KK . Impact of weight loss on plasminogen activator inhibitor-1 (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults Arterioscler Thromb Vasc Biol 1993 13:: 162–169.
Svendsen OL, Hassger C, Christiansen C, Nielsen JD, Winther K . Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen. Effect of dieting with or without exercise in overweight postmenopausal women Arterioscler Thromb Vasc Biol 1996 16:: 381–385.
Calles-Escandon J, Ballor D, Harvey-Berino J, Ades P, Tracy R, Sobel B . Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction Am J Clin Nutr 1996 64:: 7–11.
Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I . Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease Diabetes 1997 46:: 860–867.
Samad F, Yamamoto K, Loskutoff DJ . Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo J Clin Invest 1996 97:: 37–46.
Lungren CH, Brown SL, Nordt TD, Sobel BE, Fujii S . Elaboration of type 1 plasminogen activator inhibitor from adipocytes: A potential link between obesity and cardiovascular disease Circulation 1996 93:: 106–110.
Eriksson P, Reynisdottir S, Lönnqvist F, Stemme V, Hamsten A, Arner P . Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals Diabetologia 1998 41:: 65–71.
Bastard JP, Cuevas J, Cohen S, Jardel C, Hainque B . Percutaneous adipose tissue biopsy by mini-liposuction for metabolic studies JPEN Parenter Enter 1994 18:: 466–468.
Bastard JP, Bruckert E, Robert JJ, Ankri A, Grimaldi A, Jardel C, Hainque B . Are free fatty acids related to plasma plasminogen activator inhibitor-1 in android obesity? Int J Obes 1995 19:: 836–838.
Jebb S, Elia M . Techniques for the measurement of body composition: a practical guide Int J Obes 1993 17:: 611–621.
Bastard JP, Grimaldi A, Jardel C, Porquet D, Bruckert E, Hainque B . A simple index of insulin resistance Diabetes Metab 1997 23:: 87–88.
Auboeuf D, Vidal H . The use of the reverse transcription-competitive polymerase chain reaction to investigate the in vivo regulation of gene expression in small tissue samples Anal Biochem 1997 245:: 141–148.
Strandberg L, Lawrence D, Ny T . The organisation of the human plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family Eur J Biochem 1988 176:: 609–616.
Loskutoff DJ, Samad F . The adipocyte and haemostatic balance in obesity: studies of PAI-1 Arterioscler Thromb Vasc Biol 1998 18:: 1–6.
Morange P, Alessi MC, Verdier M, Casanova D, Magalon G, Juhan-Vague I . PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level Arterioscler Thromb Vasc Biol 1999 19:: 1361–1365.
Raccah D, Alessi MC, Scelles V, Menard C, Juhan-Vague I, Vague P . Plasminogen activator inhibitor activity in various types of endogenous hypertriglyceridemia Fibrinolysis 1993 7:: 171–176.
Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P . Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women Int J Obes 1998 22:: 312–317.
Acknowledgements
The authors thank Drs MC Alessi and N Ventura for the gift of human PAI-1 cDNA and for their help in the elaboration of PAI-1 mRNA assay. This work was supported by grants from Le Ministère de la Santé (Programme Hospitalier de Recherche Clinique no. AOA94042).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bastard, JP., Vidal, H., Jardel, C. et al. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 gene during very low calorie diet in obese subjects. Int J Obes 24, 70–74 (2000). https://doi.org/10.1038/sj.ijo.0801087
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0801087